



## **F-star Therapeutics to Present at SITC 2020 Virtual Annual Meeting**

**Cambridge, UK and Cambridge, MA, October 22, 2020** – F-star Therapeutics Ltd., a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb<sup>2™</sup>) antibodies, today announced that it will present two posters at the Society for Immunotherapy of Cancer's (SITC) 35<sup>th</sup> Virtual Annual Meeting being held from Monday, November 9, 2020 to Saturday, November 14, 2020.

The posters will focus on FS118, F-star's potentially first-in-class, tetravalent bispecific antibody that simultaneously blocks both the LAG-3 and PD-L1 immunosuppressive pathways. FS118 has preclinically and, in preliminary clinical data, demonstrated potent anti-tumor growth activity as well as a highly differentiated mechanism of action when compared to checkpoint monotherapies alone or in combinations.

Abstracts are available on the [SITC website](#) and the accompanying posters will be available in the Virtual Poster Hall open from 8:00 am EST on Monday, November 9, until the Virtual Poster Hall closes on December 31, 2020.

### **Details of the poster presentations:**

**Title:** A First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1, in Patients with Advanced Cancer and Resistance to PD-(L)1 Therapy

**Live Q&A:** Poster #395 – Wednesday, Nov. 11 from 5:15-5:45 p.m. EST and Friday, Nov. 13 from 4:40-5:10 p.m. EST

**Title:** FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1, Induces LAG-3 Shedding Resulting in Receptor Downregulation by T Cells via a Novel mechanism of Action

**Live Q&A:** Poster #715 – Wednesday, Nov. 11 from 5:15-5:45 p.m. EST and Friday, Nov. 13 from 4:40-5:10 p.m. EST

- END-

### **About F-star Therapeutics Ltd**

F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company's goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb<sup>2™</sup>) format, F-star's mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit [www.f-star.com](http://www.f-star.com).

**For further information, please contact:**

**For investor inquiries**

**Lindsey Trickett**

VP Investor Relations & Communications

+1 240 543 7970

[lindsey.trickett@f-star.com](mailto:lindsey.trickett@f-star.com)

**For media inquiries**

**Next Step Communications**

Nigel Smith

+1 781 326 1741

E-mail: [F-star@nextstepcomms.com](mailto:F-star@nextstepcomms.com)